Neogen Chemicals Ltd has announced that its Board of Directors will meet on March 7, 2026, to evaluate and approve a proposal for raising funds through a preferential issue of equity shares. The move is subject to shareholder and regulatory approvals, with trading restrictions already in place.
Neogen Chemicals Ltd has formally notified the exchanges that its Board of Directors will convene on Saturday, March 7, 2026, to consider a significant fundraising plan. The proposal involves issuing equity shares via preferential allotment, aligned with SEBI’s ICDR Regulations and the Companies Act, 2013.
Key Highlights
-
The fundraising will be executed through one or more tranches of equity shares
-
Pricing will be determined in accordance with Chapter V of SEBI’s ICDR Regulations
-
Approvals from shareholders, regulators, and statutory bodies will be required before execution
-
The trading window for insiders and connected persons has been closed until 48 hours after the Board meeting concludes
-
The company has uploaded the intimation on its official website under the securities announcements section
This development signals Neogen Chemicals’ intent to strengthen its capital base and pursue growth opportunities, while ensuring compliance with SEBI’s disclosure and insider trading norms.
Source: Neogen Chemicals Ltd disclosure to Stock Exchanges